Clinical trials: Aromatase Inhibitors
Breast Cancer
Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA).
- Trial name
- NCT06654570
- Testing
- Intravaginal estrogen during adjuvant letrozole
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Helsinki University Central Hospital
Breast Cancer, Xerostomia
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
The 3 Specific Aims are (1) To determine the prevalence, incidence and severity of oral conditions in postmenopausal early stage breast cancer survivors within the first 18 months of adjuvant Aromatase Inhibitor(AI) therapy, (2)…
- Trial name
- NCT01272570
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Breast Cancer
Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors
There are no data regarding the use of supplements to alleviate the musculoskeletal pain and stiffness inducted by the use of aromatase inhibitors.
- Trial name
- NCT00930527
- Testing
- Omega-3 Fatty Acid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
- Trial name
- NCT01446159
- Testing
- MEDI-573, Aromatase Inhibitor
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 188 people
- Sponsor
- MedImmune LLC
Breast Cancer Female, Osteoporosis
Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population
Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
- Trial name
- NCT04055805
- Testing
- Observational Analysis
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Musculoskeletal Pain
Targeted Physiotherapeutic Treatment for Aromatase Inhibitor-associated Musculoskeletal Pain in Breast Cancer Survivors
The primary objective of this trial is to assess the efficacy of targeted individualised physiotherapeutic treatment on aromatase inhibitor-associated musculoskeletal pain.
- Trial name
- AIMSS (NCT04560699)
- Testing
- Physiotherapeutic treatment and medical care, medical care
- Where
- Denmark
- Volunteers
- 111 people
- Sponsor
- Frederiksberg University Hospital
Luminal B/HER2-negative Breast Cancer
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.
- Trial name
- NCT05640778
- Testing
- Dalpiciclib combined with aromatase inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who…
- Trial name
- NCT01225172
- Testing
- BMS-754807, letrozole
- Where
- 21 sites in United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Periodontal Disease, Quality of Life
Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life.
- Trial name
- NCT01693731
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Breast Cancer, Vaginal Dryness
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
It is well documented that women who have breast cancer may experience a decrease in quality of life and sexual functioning due to side effects from adjuvant endocrine therapy, typically aromatase inhibitors (AIs).
- Conditions
- Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
- Trial name
- NCT01697345
- Testing
- Testosterone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Creighton University
Breast Cancer
The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women
The role of estrogens in the pathogenesis of breast cancer has been well documented. This has led to the development of "Anti-Estrogens" (selective estrogens receptor modulators and Aromatase Inhibitors), used for treatment and…
- Trial name
- NCT00566553
- Testing
- Grape Seed Extract
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms, Medication Adherence
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
Background: In women with hormone receptor positive (HR+) breast cancer, adjuvant endocrine therapy (AET) is associated with a significant survival advantage.
- Trial name
- NCT02876848
- Testing
- OPTIMUM e-health tool
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer, Estrogen Receptor Positive Breast Cancer
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
The purpose of this study is to determine the effect of exemestane on the pharmacokinetics (PK) of entinostat and to determine the effect of entinostat on the PK of exemestane in patients with locally recurrent or metastatic…
- Trial name
- NCT02820961
- Testing
- entinostat, exemestane
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Syndax Pharmaceuticals
Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
This study is being offered to patients who are post-menopausal, have breast cancer with a positive estrogen and/or progesterone hormone receptor test and are currently awaiting surgery for breast cancer.
- Trial name
- NCT01814865
- Testing
- Abiraterone Acetate, Prednisone, Aromatase Inhibitor
- Where
- 4 sites in Canada
- Sponsor
- British Columbia Cancer Agency
Idiopathic Short Stature
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
When treating very short children in puberty we are time-limited, as sex hormones cause the growth plates to fuse and growth to end.
- Trial name
- ThrasherAI (NCT01248416)
- Testing
- Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
- Where
- 4 sites in United States, Chile
- Volunteers
- 76 people
- Sponsor
- Nemours Children's Clinic
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Cognitive Side Effects of Cancer Therapy, Hypoestrogenism
ENDO-BRAIN: Effects of Endocrine Adjuvant Therapy with Aromatase Inhibitors on the Cognitive Function of Breast Cancer Patients
The principal aim of this prospective observational study is to investigate the cognitive function of breast cancer patients that use AI, comparing it with age-matched healthy controls, utilizing cognitive assessments and…
- Trial name
- ENDO-BRAIN (NCT06606535)
- Testing
- validated questionnaires, functional MRI, Optical Coherent Tomography Angiography
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ospedale Policlinico San Martino
Breast Cancer
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
The purpose of the study was to evaluate the safety and efficacy of a reduced ribociclib starting dose of 400 mg in combination with a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) for the treatment of pre…
- Trial name
- AMALEE (NCT03822468)
- Testing
- Ribociclib, Anastrozole, Letrozole
- Where
- 89 sites in United States, Argentina and 21 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Vasomotor Symptoms
Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms
Breast cancer is the most prevalent cancer type worldwide. In Egypt, It is the second most common type of cancer and the most common one in women with about 22 thousand new cases in 2020.
- Trial name
- NCT05637671
- Testing
- oxybutynin ER, Paroxetine CR
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Cairo University